Literature DB >> 11689645

Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses.

D Chen1, K F Weis, Q Chu, C Erickson, R Endres, C R Lively, J Osorio, L G Payne.   

Abstract

Cytotoxic T lymphocytes (CTL) play a vital role in host defense against viral and intracellular bacterial infections. However, nonreplicating vaccines administered by intramuscular injection using a syringe and needle elicit predominantly humoral responses and not CTL responses. Here we report that epidermal powder immunization (EPI), a technology that delivers antigens on 1.5- to 2.5-microm gold particles to the epidermis using a needle-free powder delivery system, elicits CTL responses to nonreplicating antigens. Following EPI, a majority of the antigen-coated gold particles were found in the viable epidermis in the histological sections of the target skin. Further studies using transmission electron microscopy revealed the intracellular localization of the gold particles. Many Langerhans cells (LCs) at the vaccination site contained antigen-coated particles, as revealed by two-color immunofluorescence microscopy, and these cells were found in the draining lymph nodes 20 h later. Immune responses to several viral protein antigens after EPI were studied in mice. EPI with hepatitis B surface antigen (HBsAg) and a synthetic peptide of influenza virus nucleoprotein (NP peptide) elicited antigen-specific CTL responses as well as antibody responses. In an in vitro cell depletion experiment, we demonstrated that the CTL activity against HBsAg elicited by EPI was attributed to CD8(+), not CD4(+), T cells. As controls, needle injections of HBsAg or the NP peptide into deeper tissues elicited solely antibody, not CTL, responses. We further demonstrated that EPI with inactivated A/Aichi/68 (H3N2) or A/Sydney/97 (H3N2) influenza virus elicited complete protection against a mouse-adapted A/Aichi/68 virus. In summary, EPI directly delivers protein antigens to the cytosol of the LCs in the skin and elicits both cellular and antibody responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689645      PMCID: PMC114750          DOI: 10.1128/JVI.75.23.11630-11640.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

Review 1.  DNA vaccines: a key for inducing long-term cellular immunity.

Authors:  S Gurunathan; C Y Wu; B L Freidag; R A Seder
Journal:  Curr Opin Immunol       Date:  2000-08       Impact factor: 7.486

2.  Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice.

Authors:  D Chen; R L Endres; C A Erickson; K F Weis; M W McGregor; Y Kawaoka; L G Payne
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

3.  Distribution of ATPase-positive Langerhans cells in normal adult human skin.

Authors:  H Chen; J Yuan; Y Wang; W K Silvers
Journal:  Br J Dermatol       Date:  1985-12       Impact factor: 9.302

Review 4.  HIV-peplotion vaccine. A novel approach to vaccination against AIDS by transepithelial transport of viral peptides and antigens to Langerhans cells for induction of cytolytic T cells by HLA class I and CD1 molecules for long term protection.

Authors:  Y Becker
Journal:  Adv Exp Med Biol       Date:  1996       Impact factor: 2.622

5.  On the extraordinary capacity of allogeneic epidermal Langerhans cells to prime cytotoxic T cells in vivo.

Authors:  E C McKinney; J W Streilein
Journal:  J Immunol       Date:  1989-09-01       Impact factor: 5.422

6.  Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system.

Authors:  J P Tam
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

7.  Surface densities of Langerhans cells in relation to rodent epidermal sites with special immunologic properties.

Authors:  P R Bergstresser; C R Fletcher; J W Streilein
Journal:  J Invest Dermatol       Date:  1980-02       Impact factor: 8.551

8.  Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine.

Authors:  M J Roy; M S Wu; L J Barr; J T Fuller; L G Tussey; S Speller; J Culp; J K Burkholder; W F Swain; R M Dixon; G Widera; R Vessey; A King; G Ogg; A Gallimore; J R Haynes; D Heydenburg Fuller
Journal:  Vaccine       Date:  2000-11-22       Impact factor: 3.641

9.  Sex differences in the densities of epidermal Langerhans cells of the mouse.

Authors:  Y Koyama; S Nagao; K Ohashi; H Takahashi; T Marunouchi
Journal:  J Invest Dermatol       Date:  1987-05       Impact factor: 8.551

10.  Helper activity is required for the in vivo generation of cytotoxic T lymphocytes.

Authors:  J A Keene; J Forman
Journal:  J Exp Med       Date:  1982-03-01       Impact factor: 14.307

View more
  18 in total

1.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Authors:  Igor M Belyakov; Scott A Hammond; Jeffrey D Ahlers; Gregory M Glenn; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 2.  Hepatocellular carcinoma: therapy and prevention.

Authors:  Hubert E Blum
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

Review 3.  Topical vaccination: the skin as a unique portal to adaptive immune responses.

Authors:  Chun-Ming Huang
Journal:  Semin Immunopathol       Date:  2007-04       Impact factor: 9.623

Review 4.  Skin permeabilization for transdermal drug delivery: recent advances and future prospects.

Authors:  Carl M Schoellhammer; Daniel Blankschtein; Robert Langer
Journal:  Expert Opin Drug Deliv       Date:  2014-01-07       Impact factor: 6.648

Review 5.  Micro-scale devices for transdermal drug delivery.

Authors:  Anubhav Arora; Mark R Prausnitz; Samir Mitragotri
Journal:  Int J Pharm       Date:  2008-08-30       Impact factor: 5.875

6.  Proteolistics: a biolistic method for intracellular delivery of proteins.

Authors:  Susana Martin-Ortigosa; Kan Wang
Journal:  Transgenic Res       Date:  2014-08-05       Impact factor: 2.788

Review 7.  Progress towards a needle-free hepatitis B vaccine.

Authors:  Filipa Lebre; Gerrit Borchard; Maria Conceição Pedroso de Lima; Olga Borges
Journal:  Pharm Res       Date:  2010-11-19       Impact factor: 4.200

8.  Longitudinal analysis of the T-cell receptor (TCR)-VA and -VB repertoire in CD8+ T cells from individuals immunized with recombinant hepatitis B surface antigen.

Authors:  H Höhn; C Neukirch; K Freitag; A Necker; W Hitzler; B Seliger; M J Maeurer
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

9.  Optimization of an alum-adsorbed vaccine powder formulation for epidermal powder immunization.

Authors:  Yuh-Fun Maa; Cassandra Shu; Mahmoud Ameri; Cindy Zuleger; Jenny Che; Jorge E Osorio; Lendon G Payne; Dexiang Chen
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

10.  Physicochemical and immunological characterization of N,N,N-trimethyl chitosan-coated whole inactivated influenza virus vaccine for intranasal administration.

Authors:  Niels Hagenaars; Enrico Mastrobattista; Rolf J Verheul; Imke Mooren; Harrie L Glansbeek; Jacco G M Heldens; Han van den Bosch; Wim Jiskoot
Journal:  Pharm Res       Date:  2009-02-18       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.